CD274 and neoplasm: For example, in the KEYNOTE-355 trial, pembrolizumab significantly extended survival in patients categorized as favorable for immunotherapy based on high expression of PD-L1 in tumor cells, lymphocytes, and macrophages in biopsy samples (4).